Literature DB >> 6097685

Treatment of high-risk choriocarcinoma.

K D Bagshawe.   

Abstract

Risk has different meanings even within the confines of trophoblastic disease. One unquantifiable risk for patients is treatment by physicians or surgeons with limited knowledge of this rare disease and its modern management. Risk can be immediate at the time of presentation because the disease has sometimes progressed to a life-threatening state before the diagnosis is established. Special problems at that time need consideration on the basis of which organs are involved. Placental-site trophoblastic disease presents distinctive features and requires different management. A major long-term risk is drug resistance, and a high proportion of late treatment failures in choriocarcinoma arise from inappropriate therapy at an early stage in treatment. "Prognostic," or "risk," scoring identifies the propensity of a tumor to become resistant to chemotherapy and enables treatment to be planned from the outset to minimize that risk.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097685

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

1.  Metastatic intracerebral choriocarcinoma in a teenager.

Authors:  G W Chapman
Journal:  J Natl Med Assoc       Date:  1997-11       Impact factor: 1.798

2.  Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.

Authors:  Taymaa May; Donald P Goldstein; Ross S Berkowitz
Journal:  Chemother Res Pract       Date:  2011-05-11

3.  Intramedullary spinal cord metastasis of choriocarcinoma.

Authors:  Jun Kyeung Ko; Seung Heon Cha; Jung Hwan Lee; Chang Hwa Choi
Journal:  J Korean Neurosurg Soc       Date:  2012-03-31

4.  Long-term effects of chemotherapy on lymphocyte chromosomes from patients treated for gestational trophoblastic tumours.

Authors:  B R Reeves; S D Lawler; G Casey; H Harris
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.